Navigation Links
Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
Date:9/12/2011

res is provided below.

About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations and beliefs regarding our future results or performance. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. Our actual res
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
2. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
3. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
4. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
5. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
6. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
7. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
8. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
9. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
10. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
11. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... More than half of women diagnosed with ... and still have excellent outcomes. To educate women, Agendia, ... largest sources of online consumer information about breast cancer ... provide recently diagnosed women with information sources, to help ... "We anticipate these innovative social media campaigns will ...
(Date:5/23/2013)... -- Every day, their baby stopped breathing, his collapsed bronchus blocking ... April and Bryan Gionfriddo watched helplessly, just praying ... a few doctors said he had a good chance of ... , about her now 20-month-old son, Kaiba. "At that ... take it and run with it." They found ...
(Date:5/23/2013)... MILFORD, Mass. , May 23, 2013  Spring ... for the treatment of viral infections, today announced that ... of SB 9200, its investigational, once daily, oral therapy ... conducted in healthy, HCV-infected patients and is designed to ... 9200. SB 9200 is a first-in-class drug for the ...
Breaking Medicine Technology:Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3
... Dec. 22, 2010 Haemonetics Corporation (NYSE: ... Chief Executive Officer, will present at the J.P. Morgan ... 2011 at 1:30 pm Pacific time.  The ... at http://jpmorgan.metameetings.com/webcasts/healthcare11/directlink?ticker=HAE .  The webcast ...
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today ... update webcast/conference call after the market closes on January ... Vicente Anido, Jr., Ph.D., and Chief Financial Officer and ... 2011 guidance, give a commercial and new product pipeline ...
Cached Medicine Technology:ISTA Pharmaceuticals Announces 2011 Guidance and Pipeline Update Webcast/Conference Call on January 5, 2011 2
(Date:5/25/2013)... (HealthDay News) -- Many viruses and parasites that affect ... -- a bacteria-borne illness than can result in liver ... parks, according to a veterinarian. These germs ... the air, said Dr. Susan Nelson, a clinical associate ... of these serious diseases can be fatal, even with ...
(Date:5/25/2013)... May 25, 2013 Providing patients with their ... Doc team of weight management professionals. But, aside from educating ... effectively, Diet Doc’s hCG diets also provide patients, ... during childhood like bullying, more control over their lives by ... dealing with the underlying factors of weight gain derived from ...
(Date:5/25/2013)... By working diligently for months on ... of the 2012 Lamborghini Aventador into their well-built fitments ... in the list of vehicles lined by SizeItUp for ... set to thrill automobile lovers in the year 2013. ... looks, the 2012 Lamborghini Aventador comes with extraordinarily spacious ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 According to ... most beautiful and powerful women that ever lived. Cleopatra’s ... by some of the most powerful men in her ... beauty remedies to keep her skin glowing and fresh, ... with bees- wax, maringa oil and cyprus grass. , ...
(Date:5/25/2013)... Houston, Texas (PRWEB) May 25, 2013 ... more stressful than finals week. Increasingly, they are ... them stay awake and study. For more on ... Associates, a drug treatment facility, warns that students ... through finals” are at risk for developing a ...
Breaking Medicine News(10 mins):Health News:Hidden Dangers Dog Dog Parks 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 3Health News:Rim Fitments Provider SizeItUp Launches The Database Integration For The 2012 Lamborghini Aventador 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 3Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2
... entails lower risk, speedier recovery, researchers say , , TUESDAY, ... accessing and treating ailing hearts with angioplasty may be ... catheterization technique reduces risk, bleeding, cost and patient recovery ... year, about one million Americans undergo angioplasty to open ...
... Netherlands, January 20 Elsevier today,announced the ... free online,expert-generated knowledge sharing service for the ... medical knowledge on a variety of,subjects. Designed ... research, the,website integrates a content publishing platform ...
... flooding in decades in Fiji this week, the International Fund ... working with the Fijian Government to assess the rescue needs ... overwhelming disaster for the people of Fiji. IFAW is pleased ... to save animals and minimize suffering in this time of ...
... Custom Spine announced today that Lew Bennett has been named ... Mr. Bennett brings with him over 48 years experience in ... market six times, Mr. Bennett,s love of a new challenge ... Custom Spine founder and CEO, Mahmoud Abdelgany commented, "We are ...
... today,that it has been selected as global custodian ... largest not-for-profit secular health care system.,Northern Trust will ... risk and analytical services to the Health System,s ... "North Shore-LIJ can rely on Northern Trust ...
... Jan. 20 Medicsight PLC, a subsidiary of MGT ... in the development of Computer-Aided Detection (CAD) and image ... of disease, announces that it has received a request ... and Drug Administration (FDA). This request is in regard ...
Cached Medicine News:Health News:Angioplasty Via Wrist May Be Safer 2Health News:Elsevier Launches SciTopics, the Expert-Generated Information and Collaboration Web Resource 2Health News:Elsevier Launches SciTopics, the Expert-Generated Information and Collaboration Web Resource 3Health News:IFAW Responds to Fiji Floods 2Health News:Custom Spine Announces Lew Bennett as President 2Health News:Northern Trust Named Global Custodian to North Shore-LIJ Health System in New York 2Health News:Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance 2
Primary and Posterior Stabilized Components....
... knee prosthesis stems from many years of ... manufacturing technologies have been used in order ... as a favorable pressure distribution pattern on ... to a minimum. The inherent design of ...
... The Natural Knee design ... a proprietary CSTi porous coating ... active patients, a unique bone ... deepened trochlear groove to maximize ...
Advance Posterior Stabilized Total Knee systems improves patellofemoral kinematics, reduces wear rate potential, increases resistance to posterior tibial dislocation, achieves at least 120o flexion i...
Medicine Products: